Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723078 | 0.88 | SLC6A2 (0.47) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL20117033 | 0.88 | SLC6A2 (0.47) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL917462 | 0.74 | MAPK1 (0.40) | MAPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7211602 | 0.70 | SLC6A2 (0.46) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL7214987 | 0.70 | SLC6A2 (0.46) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL7211543 | 0.69 | SLC6A2 (0.46) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL6574900 | 0.67 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HTR6CHRNB4 | |
| SCHEMBL7210015 | 0.66 | SLC6A2 (0.61) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL1546171 | 0.66 | — | — | |
| SCHEMBL25152671 | 0.65 | SLC6A2 (0.50) | MAPK1SLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | MAPK1 1112/4885SLC6A2 825/4885SLC6A4 1136/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | MAPK1 1112/4885SLC6A2 825/4885SLC6A4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.